文献速递神经免疫

贝沙罗汀治疗复发缓解型多发性硬化的安全性与疗效(CCMR One)

Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study.
PubMed 文献 · Lancet Neurol · 2021-01-01

CCMR One 是一项在英国两中心开展的随机、双盲、安慰剂对照、平行组 2a 期试验,纳入 52 例正在接受富马酸二甲酯治疗的复发缓解型多发性硬化患者,按 1:1 随机接受口服贝沙罗汀(按体表面积 300 mg/m2/日)或安慰剂治疗 6 个月。贝沙罗汀组不良事件明显更多,主要疗效指标病灶平均磁化传递率变化组间无差异,因此不推荐贝沙罗汀用于治疗多发性硬化。

要点

  • 贝沙罗汀组平均不良事件数 6·12(SD 3·09),安慰剂组 1·63(SD 1·50)。
  • 贝沙罗汀组全部 26 例均出现至少 1 起不良事件,常见中枢性甲状腺功能减退、高甘油三酯血症、皮疹和中性粒细胞减少。
  • 主要疗效指标病灶磁化传递率变化组间无差异(校正差值 0·16 pu,95%CI -0·39 至 0·71;p=0·55)。

核心结论

  • 因耐受性差且主要疗效指标为阴性,不推荐使用贝沙罗汀治疗多发性硬化患者。
  • 部分探索性 MRI 和电生理分析可见统计学显著效应,提示其他维甲酸 X 受体激动剂可能存在小的生物学效应,值得进一步研究。

研究设计与样本

  • 随机、双盲、安慰剂对照、平行组 2a 期试验(CCMR One),在英国两个中心招募复发缓解型多发性硬化患者。
  • 纳入 18-50 岁、已接受富马酸二甲酯至少 6 个月的患者,按 1:1 随机分配接受口服贝沙罗汀(按体表面积 300 mg/m2/日)或安慰剂治疗 6 个月。
  • 共 52 例参与者被随机分配,贝沙罗汀组 26 例、安慰剂组 26 例;主要安全性指标在安全性人群中分析,主要疗效指标在意向治疗人群中分析。

主要发现

  • 贝沙罗汀组平均不良事件数为 6·12(SD 3·09,共 159 起),安慰剂组为 1·63(SD 1·50,共 39 起)。
  • 贝沙罗汀组全部参与者均出现至少 1 起不良事件,包括中枢性甲状腺功能减退(26 例 vs 安慰剂组无)、高甘油三酯血症(24 例 vs 无)、皮疹(13 例 vs 1 例)和中性粒细胞减少(10 例 vs 无)。
  • 贝沙罗汀组 5 例(19%)、安慰剂组 2 例(8%)因不良事件停用研究药物;安慰剂组 1 例胆囊炎为唯一严重不良事件。
  • 主要疗效指标病灶平均磁化传递率变化在贝沙罗汀组为 0·25 个百分点(pu;SD 0·98),安慰剂组为 0·09 pu(SD 0·84),校正后贝沙罗汀-安慰剂差值为 0·16 pu(95%CI -0·39 至 0·71;p=0·55)。

关键数值与推荐

  • 贝沙罗汀用法为按体表面积 300 mg/m2/日口服,疗程 6 个月。
  • 主要疗效指标为基线磁化传递率低于患者内中位数的病灶,其平均病灶磁化传递率从基线至第 6 个月的患者水平变化。
  • 主要安全性指标为归因于贝沙罗汀的不良事件数和退出数。

临床怎么用

  • 基于本试验结果,不应将贝沙罗汀用于复发缓解型多发性硬化的治疗。
  • 贝沙罗汀治疗期间需关注中枢性甲状腺功能减退、高甘油三酯血症、皮疹和中性粒细胞减少等不良事件。
  • 探索性 MRI 和电生理分析的阳性信号提示其他维甲酸 X 受体激动剂值得进一步研究,但不能据此改变当前临床实践。

局限性

  • 样本量较小,共 52 例参与者。
  • 仅纳入 18-50 岁、已接受富马酸二甲酯至少 6 个月的复发缓解型多发性硬化患者,结果外推受限。
  • 主要疗效指标在意向治疗人群中分析,但该人群定义为本研究完成者,可能引入偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Progressive disability in multiple sclerosis occurs because CNS axons degenerate as a late consequence of demyelination. In animals, retinoic acid receptor RXR-gamma agonists promote remyelination. We aimed to assess the safety and efficacy of a non-selective retinoid X receptor agonist in promoting remyelination in people with multiple sclerosis. METHODS: This randomised, double-blind, placebo-controlled, parallel-group, phase 2a trial (CCMR One) recruited patients with relapsing-remitting multiple sclerosis from two centres in the UK. Eligible participants were aged 18-50 years and had been receiving dimethyl fumarate for at least 6 months. Via a web-based system run by an independent statistician, participants were randomly assigned (1:1), by probability-weighted minimisation using four binary factors, to receive 300 mg/m2 of body surface area per day of oral bexarotene or oral placebo for 6 months. Participants, investigators, and outcome assessors were masked to treatment allocation. MRI scans were done at baseline and at 6 months. The primary safety outcome was the number of adverse events and withdrawals attributable to bexarotene. The primary efficacy outcome was the patient-level change in mean lesional magnetisation transfer ratio between baseline and month 6 for lesions that had a baseline magnetisation transfer ratio less than the within-patient median. We analysed the primary safety outcome in the safety population, which comprised participants who received at least one dose of their allocated treatment. We analysed the primary efficacy outcome in the intention-to-treat population, which comprised all patients who completed the study. This study is registered in the ISRCTN Registry, 14265371, and has been completed. FINDINGS: Between Jan 17, 2017, and May 17, 2019, 52 participants were randomly assigned to receive either bexarotene (n=26) or placebo (n=26). Participants who received bexarotene had a higher mean number of adverse events (6·12 [SD 3·09]; 159 events in total) than did participants who received placebo (1·63 [SD 1·50]; 39 events in total). All bexarotene-treated participants had at least one adverse event, which included central hypothyroidism (n=26 vs none on placebo), hypertriglyceridaemia (n=24 vs none on placebo), rash (n=13 vs one on placebo), and neutropenia (n=10 vs none on placebo). Five (19%) participants on bexarotene and two (8%) on placebo discontinued the study drug due to adverse events. One episode of cholecystitis in a placebo-treated participant was the only serious adverse event. The change in mean lesional magnetisation transfer ratio was not different between the bexarotene group (0·25 percentage units [pu; SD 0·98]) and the placebo group (0·09 pu [0·84]; adjusted bexarotene-placebo difference 0·16 pu, 95% CI -0·39 to 0·71; p=0·55). INTERPRETATION: We do not recommend the use of bexarotene to treat patients with multiple sclerosis because of its poor tolerability and negative primary efficacy outcome. However, statistically significant effects were seen in some exploratory MRI and electrophysiological analyses, suggesting that other retinoid X receptor agonists might have small biological effects that could be investigated in further studies. FUNDING: Multiple Sclerosis Society of the United Kingdom.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Brown JWL, Cunniffe NG, Prados F, et al. Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study. Lancet Neurol. 2021. PMID: 34418398. doi:10.1016/S1474-4422(21)00179-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。